Form 4: Coeptis Therapeutics Director Chris Calise Receives Stock Options Grant

Director Chris Calise receives a grant of 5,700 non-qualified stock options in Coeptis Therapeutics Holdings, Inc.

Summary

• On March 4, 2025, Chris Calise, a director of Coeptis Therapeutics Holdings, Inc., received a grant of 5,700 non-qualified stock options under the company's 2022 equity incentive plan.
• The exercise price of these options is $10.56, which is equal to the company's stock price on the Nasdaq Capital Market on the day of the grant.
• The options will vest over one year in four equal installments, with 25% vesting on March 31, 2025, June 30, 2025, September 30, 2025, and December 31, 2025.
• The expiration date for these options is ten years from the grant date.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of stock options is a standard practice and indicates confidence in the company's future, but it's not a major event that would significantly impact the stock price.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes the director to contribute to the company's success over the next year.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel, aligning their interests with the long-term success of the company. This grant is typical for directors in publicly traded companies.

Comparison to Industry Standards

• Stock option grants for directors in similar-sized biotech companies typically range from a few thousand to tens of thousands of shares, depending on the company's stage, market capitalization, and the director's role and responsibilities.
• The vesting schedule of one year with quarterly installments is a fairly standard practice to ensure continued service and contribution from the director.
• The exercise price being set at the fair market value on the grant date is also a common practice to comply with tax regulations and ensure the options have intrinsic value.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, aligning the director's interests with the company's long-term success.
• The director is incentivized to contribute to the company's growth and profitability to increase the value of their stock options.

Key Dates